Let's talk.
We're an early team moving fast. Whether you invest, treat patients, or develop drugs, if longitudinal oncology is on your radar, reach out.
Message submitted.
We can’t confirm delivery from this page, so nothing you typed has been cleared — reopen the form to check or resend it. If you don’t hear back within a day or two, write to [email protected] and it will reach us.
Span is pre-clinical. There is no cleared assay, no prospective trial, and no patient has been treated on a Span alarm — so the most useful first message is usually a specific one: which serial-ctDNA data you have or could reach, and what you would want read off it.
If you are not sure what that message should say, the two things Span is actually asking for are written out: the retrospective serial arm for clinical and pharma readers, and the route to a first customer for investors.
The form posts to a Google Form, which is disclosed beside the submit button. If your organisation cannot route through that, email [email protected] directly and it reaches the same two people.
Investors
Pre-clinical, two founders, a methods paper and an open benchmark. The thesis, the route to a first customer and the risk are all written down before you ask. Then ask for the deck and the paper.
Read the route firstClinical & pharma partners
We are looking for one retrospective serial-ctDNA arm — detection calls, draw dates, a progression date — to score the change-point test against a pre-specified naive rule. No new samples, no protocol change, analysis and code returned.
The experiment, in fullCareers & general
Interested in the problem, or just want to learn more about what we're building? Say hello.
Get in touch